Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Payables (2016 - 2025)

IGC Pharma (IGC) has disclosed Payables for 15 consecutive years, with $628000.0 as the latest value for Q3 2025.

  • Quarterly Payables fell 18.23% to $628000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $628000.0 through Sep 2025, down 18.23% year-over-year, with the annual reading at $883000.0 for FY2025, 14.23% up from the prior year.
  • Payables for Q3 2025 was $628000.0 at IGC Pharma, down from $933000.0 in the prior quarter.
  • The five-year high for Payables was $1.9 million in Q1 2021, with the low at $360000.0 in Q4 2021.
  • Average Payables over 5 years is $874052.6, with a median of $773000.0 recorded in 2024.
  • The sharpest move saw Payables crashed 68.06% in 2021, then soared 119.95% in 2022.
  • Over 5 years, Payables stood at $360000.0 in 2021, then rose by 29.44% to $466000.0 in 2022, then surged by 39.06% to $648000.0 in 2023, then increased by 28.86% to $835000.0 in 2024, then dropped by 24.79% to $628000.0 in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $628000.0, $933000.0, and $883000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.